Chemomab Therapeutics (NASDAQ:CMMB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock opened at $1.41 on Friday. The business has a 50 day simple moving average of $2.14 and a two-hundred day simple moving average of $1.86. Chemomab Therapeutics has a 12 month low of $1.05 and a 12 month high of $3.58. The stock has a market capitalization of $10.22 million, a P/E ratio of -0.66 and a beta of 0.74.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings results on Thursday, August 20th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12).

Institutional Trading of Chemomab Therapeutics

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC increased its position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 19.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 61,710 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Kestra Private Wealth Services LLC owned about 0.86% of Chemomab Therapeutics worth $97,000 at the end of the most recent reporting period. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is based on the role of CCL24, a chemokine believed to contribute to inflammation, tissue remodeling and fibrosis across multiple organs.

Chemomab’s lead product candidate is CM-101, an investigational monoclonal antibody designed to block CCL24 activity. The company is evaluating CM-101 in diseases including systemic sclerosis, also known as scleroderma, and primary sclerosing cholangitis, a chronic liver disease.